Tags

Type your tag names separated by a space and hit enter

Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients.
Allergy. 2009 Apr; 64(4):596-604.A

Abstract

BACKGROUND

Nonsedating H(1)-antihistamines are recommended for the treatment of urticaria by the recent EAACI/GA(2)LEN/EDF guidelines. The aim of this study was to compare the efficacy, after 4 weeks of treatment, with levocetirizine 5 mg and desloratadine 5 mg, both once daily in the morning, in symptomatic chronic idiopathic urticaria (CIU) patients.

METHODS

This multi-center, randomized, double-blind study involved 886 patients (438 on levocetirizine and 448 on desloratadine). The primary objective was to compare their efficacy on the mean pruritus severity score after 1 week of treatment. Mean pruritus severity score over 4 weeks and pruritus duration score, number and size of wheals, mean CIU composite score (sum of the scores for pruritus severity and numbers of wheals), quality of life, and the patient's and investigator's global satisfaction with treatment, were secondary efficacy measures.

RESULTS

Levocetirizine led to a significantly greater decrease in pruritus severity than desloratadine over the first treatment week; mean pruritus severity scores of 1.02 and 1.18 for levocetirizine and desloratadine, respectively (P < 0.001). The result was similar for the entire 4-week treatment period (P = 0.004). In addition, levocetirizine decreased pruritus duration and the mean CIU composite scores to a significantly greater extent than desloratadine during the first week (P = 0.002 and 0.005, respectively) and over the entire study (P = 0.009 and P < 0.05, respectively). Similarly, levocetirizine increased the patients' global satisfaction after one and 4 weeks (P = 0.012 and 0.021, respectively), compared with desloratadine. Safety and tolerability were similar in both groups.

CONCLUSIONS

Levocetirizine 5 mg was significantly more efficacious than desloratadine 5 mg in the treatment of CIU symptoms.

Links

Aggregator Full Text

Authors+Show Affiliations

Potter PC
University of Cape Town Lung Institute, South Africa.
Kapp A
No affiliation info available
Maurer M
No affiliation info available
Guillet G
No affiliation info available
Jian AM
No affiliation info available
Hauptmann P
No affiliation info available
Finlay AY
No affiliation info available

MeSH

CetirizineChronic DiseaseDouble-Blind MethodFemaleHistamine H1 Antagonists, Non-SedatingHumansLoratadineMalePruritusQuality of LifeSeverity of Illness IndexUrticaria

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19053988

Citation

Potter, P C., et al. "Comparison of the Efficacy of Levocetirizine 5 Mg and Desloratadine 5 Mg in Chronic Idiopathic Urticaria Patients." Allergy, vol. 64, no. 4, 2009, pp. 596-604.
Potter PC, Kapp A, Maurer M, et al. Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy. 2009;64(4):596-604.
Potter, P. C., Kapp, A., Maurer, M., Guillet, G., Jian, A. M., Hauptmann, P., & Finlay, A. Y. (2009). Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy, 64(4), 596-604. https://doi.org/10.1111/j.1398-9995.2008.01893.x
Potter PC, et al. Comparison of the Efficacy of Levocetirizine 5 Mg and Desloratadine 5 Mg in Chronic Idiopathic Urticaria Patients. Allergy. 2009;64(4):596-604. PubMed PMID: 19053988.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. AU - Potter,P C, AU - Kapp,A, AU - Maurer,M, AU - Guillet,G, AU - Jian,A M, AU - Hauptmann,P, AU - Finlay,A Y, Y1 - 2008/11/11/ PY - 2008/12/5/pubmed PY - 2009/5/27/medline PY - 2008/12/5/entrez SP - 596 EP - 604 JF - Allergy JO - Allergy VL - 64 IS - 4 N2 - BACKGROUND: Nonsedating H(1)-antihistamines are recommended for the treatment of urticaria by the recent EAACI/GA(2)LEN/EDF guidelines. The aim of this study was to compare the efficacy, after 4 weeks of treatment, with levocetirizine 5 mg and desloratadine 5 mg, both once daily in the morning, in symptomatic chronic idiopathic urticaria (CIU) patients. METHODS: This multi-center, randomized, double-blind study involved 886 patients (438 on levocetirizine and 448 on desloratadine). The primary objective was to compare their efficacy on the mean pruritus severity score after 1 week of treatment. Mean pruritus severity score over 4 weeks and pruritus duration score, number and size of wheals, mean CIU composite score (sum of the scores for pruritus severity and numbers of wheals), quality of life, and the patient's and investigator's global satisfaction with treatment, were secondary efficacy measures. RESULTS: Levocetirizine led to a significantly greater decrease in pruritus severity than desloratadine over the first treatment week; mean pruritus severity scores of 1.02 and 1.18 for levocetirizine and desloratadine, respectively (P < 0.001). The result was similar for the entire 4-week treatment period (P = 0.004). In addition, levocetirizine decreased pruritus duration and the mean CIU composite scores to a significantly greater extent than desloratadine during the first week (P = 0.002 and 0.005, respectively) and over the entire study (P = 0.009 and P < 0.05, respectively). Similarly, levocetirizine increased the patients' global satisfaction after one and 4 weeks (P = 0.012 and 0.021, respectively), compared with desloratadine. Safety and tolerability were similar in both groups. CONCLUSIONS: Levocetirizine 5 mg was significantly more efficacious than desloratadine 5 mg in the treatment of CIU symptoms. SN - 1398-9995 UR - https://www.unboundmedicine.com/medline/citation/19053988/Comparison_of_the_efficacy_of_levocetirizine_5_mg_and_desloratadine_5_mg_in_chronic_idiopathic_urticaria_patients_ L2 - https://doi.org/10.1111/j.1398-9995.2008.01893.x DB - PRIME DP - Unbound Medicine ER -